← Back to Search

N/A

Radiation vs. Radiation + Lymph Node Dissection for Breast Cancer

Phase 3
Waitlist Available
Research Sponsored by Alliance for Clinical Trials in Oncology
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This trial is comparing radiation therapy alone to radiation therapy with lymph node dissection in treating breast cancer patients who have already had chemotherapy and surgery.

Who is the study for?
This trial is for breast cancer patients who've finished chemotherapy and surgery, with certain hormone receptor statuses checked. They should have a performance status of 0-1, indicating they're fully active or restricted in physically strenuous activity but ambulatory. Participants must not be pregnant, have no history of invasive cancer in the opposite breast within 5 years (except certain skin cancers or cervical carcinoma in situ), and no prior radiation therapy.
What is being tested?
The study compares two approaches after chemotherapy and surgery: one group undergoes axillary lymph node dissection (ALND) where lymph nodes are surgically removed; another receives only axillary radiation therapy to destroy any remaining cancer cells. The goal is to determine which method is more effective for treating breast cancer that has spread to nearby lymph nodes.
What are the potential side effects?
Potential side effects from ALND may include pain, swelling, limited arm movement, nerve injury causing numbness or weakness, and risk of lymphedema (arm swelling due to fluid buildup). Radiation therapy might cause skin changes like redness and irritation, fatigue, arm swelling as well as a slight risk of secondary cancers.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: Axillary radiation and nodal radiation therapyExperimental Treatment2 Interventions
Radiation Therapy: Radiation is delivered to the breast/chest wall, full axilla including Levels I, II, III, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.
Group II: Arm 1: ALND + nodal radiation therapyExperimental Treatment2 Interventions
Surgery: For patients randomized to axillary lymph node dissection (ALND), it is recommended that a complete level I and II dissection with resection of minimum of a total of 8 lymph nodes (SLN and ALND together) be done. Level III dissection is not required, but may be performed at the discretion of the surgeon. If fewer than 8 lymph nodes (SLN and ALND together) are resected, then the patient will discontinue protocol treatment. Radiation Therapy: Radiation is delivered to the breast/chest wall, undissected axilla, supraclavicular nodes and internal mammary nodes in the first 3 intercostal spaces. Treatment will be given 5 days a week over 5-6 weeks.

Find a Location

Who is running the clinical trial?

Alliance for Clinical Trials in OncologyLead Sponsor
518 Previous Clinical Trials
220,325 Total Patients Enrolled
75 Trials studying Breast Cancer
40,143 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,957 Previous Clinical Trials
41,110,105 Total Patients Enrolled
943 Trials studying Breast Cancer
1,443,132 Patients Enrolled for Breast Cancer
Canadian Cancer Trials GroupNETWORK
132 Previous Clinical Trials
67,855 Total Patients Enrolled
9 Trials studying Breast Cancer
8,724 Patients Enrolled for Breast Cancer
Judy Boughey, MDStudy ChairMayo Clinic
2 Previous Clinical Trials
1,026 Total Patients Enrolled
2 Trials studying Breast Cancer
1,026 Patients Enrolled for Breast Cancer

Media Library

Axillary Lymph Node Dissection (ALND) (N/A) Clinical Trial Eligibility Overview. Trial Name: NCT01901094 — Phase 3
Breast Cancer Research Study Groups: Arm 1: ALND + nodal radiation therapy, Arm 2: Axillary radiation and nodal radiation therapy
Breast Cancer Clinical Trial 2023: Axillary Lymph Node Dissection (ALND) Highlights & Side Effects. Trial Name: NCT01901094 — Phase 3
Axillary Lymph Node Dissection (ALND) (N/A) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01901094 — Phase 3
~0 spots leftby Jan 2025